In vivo anti-tumor activity of photodynamic therapy with intravenous administration of acridine orange, followed by illumination with high-power flash wave light in a mouse osteosarcoma model

Introduction

Effort has been devoted to preserving excellent limb function with a low risk of local tumor recurrence after marginal or intralesional tumor resection. Thus, over the past 10 years, we have engaged in the development of photodynamic and radiodynamic therapy with acridine orange (AO-PDT and AO-RDT) as a minimally invasive surgery for the treatment of musculoskeletal sarcomas. Numerous clinical trials for this treatment modality conducted thus far have shown to be successful (1–7). However, in these clinical studies on AO-PDT and AO-RDT, AO was administered by local and not by intravenous injection. Furthermore, AO excitation was achieved using continuous wave light (CWL) derived from a xenon lamp, as opposed to a high-power flash wave light (FWL) from a xenon lamp that has been demonstrated in previous studies to exert a stronger cytocidal effect, as compared to CWL, using a mouse osteosarcoma cell line (8,9). These studies also showed that the intravenous administration of AO may be useful for the photodynamic diagnosis (PDD) of mouse osteosarcoma, without entailing any complications (10). Therefore, using a mouse osteosarcoma model, we undertook to clarify the anti-tumor activity of AO-PDT with FWL after the intravenous administration of AO.

Materials and methods

Mouse osteosarcoma model

LM8, the mouse osteosarcoma cell line used in the present study, was derived from Dunn’s osteosarcoma which possesses strong metastasizing ability (11). LM8 cells were harvested in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum at 37°C in a 5% CO2 atmosphere. A suspension containing 1×106 cells isolated from the culture dishes by trypsinization was inoculated into the soft tissues, including the subcutaneous tissue and muscles of the back, at the site of implantation in C3H mice after removal of the hair (5-week-old males; Japan SLC. Inc., Shizuoka, Japan). The subsequent experiments described below were conducted on tumors that grew to a macroscopically detectable size (>3 mm in diameter) within 10 days.

Light sources

A xenon lamp was used as the source of the flash wave light (FWL) (12). The illumination machine KFS-30HJ (Ushio Electric Inc., Tokyo, Japan) was used for the FWL illumination. The FWL light illumination frequency was 60 Hz and the pulse width was <1 ms. The energy generated by one-shot illumination with FWL was 15 J and the illumination level was 1,000,000 lux.

Tumor growth inhibition by AO-PDT using FWL

The tumor-bearing mice were divided randomly into 4 groups of 5 mice each: group 1, no treatment (AO−/L−); group 2, illumination with FWL alone for 10 min (AO−/10 min FWL); group 3, intravenous administration of AO at 1.0 mg/kg alone (1.0 mg/kg AO/L−) and group 4, intravenous administration of AO at 1.0 mg/kg AO followed by illumination with FWL for 10 min (1.0 mg/kg AO/10 min FWL). The tumor-bearing mice administered with AO via the tail vein were exposed to FWL illumination for 10 min at 2 h after the AO injection. Fig. 1 shows the system used for the FWL illumination of the mice. Mice administered with AO were set in a stainless steel bowl under anesthesia induced by intraperitoneally administered pentobarbital sodium, and then exposed to FWL illumination from the illumination machine KFS-30HJ for 10 min. The tumor volume was sequentially calculated, until 28 days after this treatment, from the measured values of the maximum and minimum diameters as maximum diameter × minimum diameter 2/2 (13). AO was used at a concentration of 1.0 mg/kg, since previous studies showed that this concentration yields the strongest cytocidal effect and lowest toxicity in mice (10). The illumination time (10 min) and time-point of illumination (2 h after AO injection) were also selected based on the results of previous studies (9,10,14,15).

Figure 1 The system of flash wave light (FWL) illumination of tumor-bearing mice is shown.

Histological and immunohistochemical responses

The histological responses to AO-PDT using FWL were comparatively evaluated in groups 1 and 4 three days after the treatment, using sections of the resected tumors stained with hematoxylin and eosin. Immunohistochemical analysis by TdT-mediated dUTP-biotin nick end-labeling (TUNEL) was also performed in group 4.

Statistical analysis

Statistical analysis was performed using the StatView statistical software (version 5.0; SAS Institute Inc., Cary, NC, USA). Significant differences among the various groups were evaluated using Student’s t-test. P<0.05 was considered to be significant.

Experiments were performed in accordance with the guidelines in the Declaration of Helsinki and the Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing and Education.

Results

Tumor growth inhibition by AO-PDT using FWL

A significant decrease in the tumor volume was observed in group 4 (1.0 mg/kg AO/10 min FWL) as compared to that in groups 1 (AO−/L−) (p<0.02), 2 (AO−/10 min FWL) (p<0.05) or 3 (1.0 mg/kg AO/L−) (p<0.04). The tumor volume tended to decrease in group 3 as compared to that in groups 1 or 2. However, there were no significant differences among the three groups (Fig. 2).

Figure 2 Growth of mouse osteosarcomas after intravenous injection of AO at 1.0 mg/kg, followed by illumination with FWL. A significant decrease of the tumor volume was noted in group 4 (1.0 mg/kg AO/10 min FWL) as compared to that in groups 1 (AO−/L−) (p<0.02), 2 (AO−/10 min FWL) (p<0.05) and 3 (1.0 mg/kg AO/L−) (p<0.04).

Histological and immunohistochemical responses

A histological examination of the tumors showed substantial cell necrosis in group 4, but not in group 1. The surviving tumor cells in group 4 showed large pyknotic nuclei (Fig. 3). Immunohistochemical analysis by TUNEL assay revealed the presence of numerous apoptotic cells (Fig. 4).

Figure 3 Histological findings in the mouse osteosarcoma xenografts in (A) group 1 (AO−/L−) and (B) group 4 (1.0 mg/kg AO/10 min FWL), three days after AO-PDT (H&E stain; original objective lens, ×10).

Figure 4 Findings of TUNEL assay in the mouse osteosarcoma xenografts in (A) group 1 (AO−/L−) and (B) group 4 (1.0 mg/kg AO/10 min FWL), three days after AO-PDT (original objective lens, ×10).

Discussion

Our previous intensive basic investigation and clinical trials showed the strong cytocidal effect of photodynamic and/or radiodynamic therapy with acridine orange (AO-PDT and AO-RDT). Findings suggest that this type of treatment modality is useful with minimally invasive surgery for patients with high-grade malignant musculoskeletal sarcomas, as it allows for the maintenance of excellent limb function and is correlated with a low risk of local recurrence (3–10,14–19). However, further improvements in the techniques of this innovative modality are required. At present, in clinical AO-PDT, AO is administrated locally, not systemically, and any residual tumor after intralesional resection is illuminated by CWL from a xenon lamp. We contended that for the homogeneous uptake of AO by the entire tumor burden in the human body, intravenous administration may be better than local administration and that stronger excitation with a high-power light may yield a stronger cytocidal effect. To confirm the latter hypothesis, we performed an in vitro study using a mouse osteosarcoma cell line in which AO-PDT was achieved using high-power FWL, which is commonly used for strobe photos and has a stronger illumination at lower energy levels than CWL. After a 10-min illumination and following exposure to AO at the concentration of 1.0 mg/ml, FWL showed a stronger cytocidal effect than CWL on the mouse osteosarcoma cell line, LM8 (9). Consequently, this in vivo study was conducted. Previously, we reported that the intraperitoneal administration of AO at 10 mg/kg followed by blue light excitation inhibited the tumor growth of osteosarcoma developing from a different cell line (MOS) than LM8 in vivo (14,15,18,19). Recently, we also found that the intravenous administration of AO at 1.0 mg/kg is useful for PDD of mouse osteosarcomas in nude mice. AO initially binds to both tumor and normal tissues, such as muscles and adipose tissue. However, after 2 h AO is quickly excluded from the normal, but not malignant, tissues. This exclusion produces a significant difference of the AO fluorescence intensity between tumor and normal tissues, thereby allowing visualization of the tumor tissue alone which fluoresces under blue excitation light. In the PDD study, we determined that the LD50 of the intravenously administered AO was 27.3 mg/kg and that none of the mice showed fetal complications after administration of the compound at a dose of <27.3 mg/kg. Therefore, AO at the concentration of 1.0 mg/kg should be safe for humans (10).

The findings of this study showed that the growth of mouse osteosarcoma tumors was significantly inhibited in the group treated with AO-PDT using FWL following the intravenous administration of AO, as compared with that in the control groups, including the non-treatment, AO-alone and FWL-alone treatment groups. Histological and immunohistochemical examinations on day 3, following AO-PDT, showed that apoptosis and necrosis were induced in the tumor cells (20,21), although we have yet to clarify the precise genetic pathway leading to cell death induced by AO-PDT. None of the mice treated with AO-PDT died. Therefore, we hypothesize that AO-PDT, with AO intravenously administered at 1.0 mg/kg, followed by excitation using FWL, shows cytocidal effects against osteosarcoma cells. As demonstrated in our previous in vitro study, the use of FWL for AO-PDT yields a stronger cytocidal effect than that of CWL (9). Since the results showed that the intravenous administration of AO at 1.0 mg/kg is useful for AO-PDT and is safe for mice, AO may also be applicable in humans, although intensive clinical studies are needed to confirm the efficacy and toxicity of AO administered by intravenous injection.

In conclusion, AO-PDT using FWL, following the intravenous administration of AO, exerted strong anti-tumor activity against the primary tumor. Consequently, this treatment modality is applicable for the treatment of sarcomas as well as carcinomas in humans, and in future, will be employed as an innovative modality for cancer therapy.

References